CHMP greenlights first two CAR-T cell therapies in the EU
The EMA’s CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Improving models of chronic hepatitis
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
GMO acreage growing globally
Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Chugai ends licence for PharmaMar’s lurbinectedin
Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
Microbial game-changers
How do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.
Inflammasome specialist NodThera Ltd raises €31.8m
Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.
Researchers identify T cell guardians of the intestine
Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.
Afatinib push back K-RAS-positive lung cancer
A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Novimmune enters US$195m option deal with TG Therapeutics Inc.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.
Chemspec Europe 2018 starting
For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).